Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/14/2025 | $31.00 → $22.00 | Equal-Weight → Underweight | Morgan Stanley |
| 11/20/2024 | Hold → Reduce | Kepler | |
| 9/9/2024 | $24.00 | Market Perform | Leerink Partners |
| 8/2/2024 | Outperform → Mkt Perform | Raymond James | |
| 3/28/2024 | $41.00 → $31.00 | Neutral → Underperform | BofA Securities |
| 3/7/2024 | $38.00 | Equal-Weight | Morgan Stanley |
| 8/24/2023 | Buy → Neutral | Citigroup | |
| 5/5/2023 | Mkt Perform → Outperform | Raymond James |
Appoints Sooin Kwon as Chief Business Officer and Dan Grossman as Chief Strategy Officer Both executives possess proven track records in strategic execution and deal-making and will help drive long-term value creation at Galapagos Mechelen, Belgium; July 23, 2025, 22.01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointments of Ms. Sooin Kwon as Chief Business Officer (CBO) and Mr. Dan Grossman as Chief Strategy Officer (CStO), effective August 4, 2025, further strengthening the Company's leadership team. They will both report to Henry Gosebruch, CEO, and join the Company's Management Committee. "We are excited to welcome Sooin and Dan to our senior leadership," said
New Directors bring deep commercial, operational, and transaction experience to the Board Mechelen, Belgium; July 23, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointments by way of co-optation of Dawn Svoronos and Jane Griffiths as Non-Executive Independent Directors to its Board of Directors, effective July 28, 2025. Dawn Svoronos and Jane Griffiths will replace Peter Guenter and Simon Sturge, who will step down from the Board on July 28, 2025. Jérôme Contamine, Chair of the Board, said: "We are very pleased to welcome Dawn and Jane to our Board of Directors. Their appointments further strengthen the Board and underscore our commitment to long-term v
Appointments of new CEO, CFO, and seasoned business development leaders with proven track records of executing strategic transactions will position the Company to drive shareholder value and advance pipeline expansion Strategic alternatives for the cell therapy business, including a potential divestiture, are being evaluated; CAR-T programs maintain positive momentum with recently presented clinical data Strong balance sheet with €3.1 billion in cash and financial investments as of June 30, 2025Mechelen, Belgium; July 23, 2025, 22:01 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced its half-year 2025 financial results and provided a
Morgan Stanley downgraded Galapagos NV from Equal-Weight to Underweight and set a new price target of $22.00 from $31.00 previously
Kepler downgraded Galapagos NV from Hold to Reduce
Leerink Partners initiated coverage of Galapagos NV with a rating of Market Perform and set a new price target of $24.00
Appoints Sooin Kwon as Chief Business Officer and Dan Grossman as Chief Strategy Officer Both executives possess proven track records in strategic execution and deal-making and will help drive long-term value creation at Galapagos Mechelen, Belgium; July 23, 2025, 22.01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointments of Ms. Sooin Kwon as Chief Business Officer (CBO) and Mr. Dan Grossman as Chief Strategy Officer (CStO), effective August 4, 2025, further strengthening the Company's leadership team. They will both report to Henry Gosebruch, CEO, and join the Company's Management Committee. "We are excited to welcome Sooin and Dan to our senior leadership," said
New Directors bring deep commercial, operational, and transaction experience to the Board Mechelen, Belgium; July 23, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointments by way of co-optation of Dawn Svoronos and Jane Griffiths as Non-Executive Independent Directors to its Board of Directors, effective July 28, 2025. Dawn Svoronos and Jane Griffiths will replace Peter Guenter and Simon Sturge, who will step down from the Board on July 28, 2025. Jérôme Contamine, Chair of the Board, said: "We are very pleased to welcome Dawn and Jane to our Board of Directors. Their appointments further strengthen the Board and underscore our commitment to long-term v
Appointments of new CEO, CFO, and seasoned business development leaders with proven track records of executing strategic transactions will position the Company to drive shareholder value and advance pipeline expansion Strategic alternatives for the cell therapy business, including a potential divestiture, are being evaluated; CAR-T programs maintain positive momentum with recently presented clinical data Strong balance sheet with €3.1 billion in cash and financial investments as of June 30, 2025Mechelen, Belgium; July 23, 2025, 22:01 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced its half-year 2025 financial results and provided a
6-K - GALAPAGOS NV (0001421876) (Filer)
6-K - GALAPAGOS NV (0001421876) (Filer)
6-K - GALAPAGOS NV (0001421876) (Filer)
First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028 Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and Henry Gosebruch appointed Founding CEO of Galapagos subsidiary SpinCo €3.3 billion in cash and financial investments as of March 31, 2025; Normalized annual cash burn guidance, excluding restructuring costs, in the range of €175 million -
Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein Focusing on accelerating GLPG5101 program, expanding to eight indications with significant unmet needs, and aiming for first approval by 2028 Plan to separate into two companies listed on Nasdaq and Euronext, with SpinCo to build a pipeline through deals and Galapagos to advance novel cell therapies for cancers of high unmet need Management to host conference call tomorrow, February 13, 2025, at 14:00 CET / 8:00 am ET Mechelen, Belgium; February 12, 2025, 22:01 CET; regulated information – G
Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions Galapagos will gain full global development and commercialization rights to its pipeline, focusing on accelerating cell therapies and building a global, decentralized manufacturing network Galapagos to implement a strategic reorganization to position the Company for long-term growth and cell therapy leadership in oncologyManagement to host conference call today at 14:00 CET / 8:00 am ET MECHELEN, Belgium – January 8, 2025 – 07:30 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GL
SC 13G/A - GALAPAGOS NV (0001421876) (Subject)
SC 13D/A - GALAPAGOS NV (0001421876) (Subject)
SC 13D - GALAPAGOS NV (0001421876) (Subject)